Bioequivalence and Bioavailability Forum 01:42 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

FDA views on the use of R and other nonproprietary software [Software]

posted by ElMaestro - Denmark, 2017-11-24 19:33  - Posting: # 18002
Views: 927

Hi all,

I stumbled upon this presentation by chance.

The future looks bright for R.

A good weekend to all of you.

if (3) 4

x=c("Foo", "Bar")
b=data.frame(x)
typeof(b[,1]) ##aha, integer?
b[,1]+1 ##then let me add 1



Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,154 posts in 4,080 threads, 1,308 registered users;
online 9 (0 registered, 9 guests [including 7 identified bots]).

One can show the following: given any rule, however “fundamental”
or “necessary” for science, there are always circumstances
when it is advisable not only to ignore the rule,
but to adopt its opposite.    Paul Feyerabend

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed